Yokoi K, Miyazawa N, Mori K, Saito Y, Tominaga K, Matsui M, Kitagawa T
Divisions of Thoracic Diseases and Radiation Therapy, Tochigi Cancer Center, Utsunomiya, Japan.
Kyobu Geka. 1993 Jan;46(1):26-30.
From February 1988 to September 1992, six patients with Stage III or IV invasive thymoma were enrolled onto our study of multidisciplinary treatment, which included chemotherapy, surgery, and radiotherapy. The chemotherapy consisted of cisplatin (20 mg/m2 continuous 24-hour infusion on days 1 through 4), doxorubicin (40 mg/m2 on day 1), and methylprednisolone (1,000 mg on days 1 through 4 and 500 mg days 5 and 6). Two patients received surgery (incomplete resection) and postoperative chemo/radiotherapy, and four patients received induction chemotherapy followed by surgery and chemo/radiotherapy. All patients with induction chemotherapy showed a partial response and underwent complete (n = 2) or partial (n = 2) resection. Four patients are alive with no evidence of disease for 31 to 55 months after the diagnoses. But two with partial resection after chemotherapy died of recurrent disease. Multidisciplinary treatment including chemotherapy may be a new therapeutic choice in management of advanced invasive thymoma.
1988年2月至1992年9月,6例Ⅲ期或Ⅳ期浸润性胸腺瘤患者纳入我们的多学科治疗研究,该治疗包括化疗、手术和放疗。化疗方案为顺铂(第1至4天,20 mg/m²持续24小时输注)、阿霉素(第1天,40 mg/m²)和甲泼尼龙(第1至4天,1000 mg,第5和6天,500 mg)。2例患者接受了手术(不完全切除)及术后化疗/放疗,4例患者接受诱导化疗,随后进行手术及化疗/放疗。所有接受诱导化疗的患者均有部分缓解,并接受了根治性(n = 2)或姑息性(n = 2)切除。4例患者在确诊后31至55个月存活,无疾病证据。但2例化疗后接受部分切除的患者死于疾病复发。包括化疗在内的多学科治疗可能是晚期浸润性胸腺瘤治疗的一种新选择。